Pegsunercept

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Pegsunercept
Clinical data
  • investigational
subcutaneous injection
Pharmacokinetic data
Bioavailability N/A
Identifiers
330988-75-5 N
None
UNII Q5I7SFZ853 YesY
KEGG D05393 YesY
Chemical data
Formula C502H758N154O165S16
12,103 g/mol (protein part)
 N (what is this?)  (verify)

Pegsunercept is a drug for the treatment of rheumatoid arthritis. As of January 2010, Phase II clinical trials have been completed.[1][2][3] It is being developed by Amgen.

Similarly to etanercept, pegsunercept is a soluble tumor necrosis factor receptor. Pegsunercept is a PEGylated protein.[3]

References[edit]

  1. ^ Clinical trial number NCT00037700 for "Evaluation of the Efficacy of Combination Treatment With Anakinra and Pegsunercept in Improving Rheumatoid Arthritis" at ClinicalTrials.gov
  2. ^ Clinical trial number NCT00111423 for "Evaluating the Safety of Extended Treatment With Pegsunercept (PEG sTNF-RI)in Subjects With Rheumatoid Arthritis (RA)" at ClinicalTrials.gov
  3. ^ a b Furst, D.; Fleischmann, R.; Kopp, E.; Schiff, M.; Edwards C, 3.; Solinger, A.; Macri, M.; 990136 Study, G. (2005). "A phase 2 dose-finding study of PEGylated recombinant methionyl human soluble tumor necrosis factor type I in patients with rheumatoid arthritis". The Journal of rheumatology 32 (12): 2303–2310. PMID 16331754.  edit